Literature DB >> 23772029

Orchestration of CD4 T cell epitope preferences after multipeptide immunization.

Jacqueline Tung1, Andrea J Sant.   

Abstract

A detailed understanding of the molecular and cellular mechanisms that underlie epitope preferences in T cell priming is important for vaccines designed to elicit a broad T cell response. Protein vaccinations generally elicit CD4 T cell responses that are skewed toward a small fraction of epitopes, a phenomenon known as immunodominance. This characteristic of T cell responses, which limits the diversity of CD4 T cell recognition, is generally attributed to intracellular Ag processing. However, we recently discovered that immunodominance hierarchies persist even after vaccination with synthetic peptides. In this study, we probed the regulatory mechanisms that cause diminished CD4 T cell responses to subdominant peptides after such multipeptide immunization in mice. We have found that the delivery of subdominant and dominant epitopes on separate dendritic cells rescues expansion of less favored CD4 T cells. Furthermore, through the use of genetic models and inhibitors, we have found that selective losses in CD4 T cell responses are mediated by an IFN-γ-induced pathway, involving IDO, and that regulatory T cell activities may also regulate preferences in CD4 T cell specificity. We propose that after multipeptide immunization, the expansion and differentiation of dominant T cells initiate complex regulatory events that determine the final peptide specificity of the elicited CD4 T cell response.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23772029      PMCID: PMC3742317          DOI: 10.4049/jimmunol.1300312

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  65 in total

Review 1.  Epitope-based vaccines: an update on epitope identification, vaccine design and delivery.

Authors:  Alessandro Sette; John Fikes
Journal:  Curr Opin Immunol       Date:  2003-08       Impact factor: 7.486

Review 2.  Epitope dominance, competition and T cell affinity maturation.

Authors:  Ross M Kedl; John W Kappler; Philippa Marrack
Journal:  Curr Opin Immunol       Date:  2003-02       Impact factor: 7.486

Review 3.  Development and function of CD25+CD4+ regulatory T cells.

Authors:  Zoltán Fehérvari; Shimon Sakaguchi
Journal:  Curr Opin Immunol       Date:  2004-04       Impact factor: 7.486

4.  Competition for self-peptide-MHC complexes and cytokines between naive and memory CD8+ T cells expressing the same or different T cell receptors.

Authors:  Qing Ge; Ailin Bai; Brendan Jones; Herman N Eisen; Jianzhu Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-19       Impact factor: 11.205

5.  What is trogocytosis and what is its purpose?

Authors:  Etienne Joly; Denis Hudrisier
Journal:  Nat Immunol       Date:  2003-09       Impact factor: 25.606

6.  Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase.

Authors:  David H Munn; Madhav D Sharma; Jeffrey R Lee; Kanchan G Jhaver; Theodore S Johnson; Derin B Keskin; Brendan Marshall; Phillip Chandler; Scott J Antonia; Russell Burgess; Craig L Slingluff; Andrew L Mellor
Journal:  Science       Date:  2002-09-13       Impact factor: 47.728

Review 7.  IDO expression by dendritic cells: tolerance and tryptophan catabolism.

Authors:  Andrew L Mellor; David H Munn
Journal:  Nat Rev Immunol       Date:  2004-10       Impact factor: 53.106

8.  Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion.

Authors:  Andrew L Mellor; Babak Baban; Phillip Chandler; Brendan Marshall; Kanchan Jhaver; Anna Hansen; Pandelakis A Koni; Makio Iwashima; David H Munn
Journal:  J Immunol       Date:  2003-08-15       Impact factor: 5.422

9.  Interferon gamma is required for activation-induced death of T lymphocytes.

Authors:  Yosef Refaeli; Luk Van Parijs; Stephen I Alexander; Abul K Abbas
Journal:  J Exp Med       Date:  2002-10-07       Impact factor: 14.307

10.  Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase.

Authors:  Guido Frumento; Rita Rotondo; Michela Tonetti; Gianluca Damonte; Umberto Benatti; Giovanni Battista Ferrara
Journal:  J Exp Med       Date:  2002-08-19       Impact factor: 14.307

View more
  6 in total

1.  Heterologous viral protein interactions within licensed seasonal influenza virus vaccines.

Authors:  Marina Koroleva; Frances Batarse; Savannah Moritzky; Carole Henry; Francisco Chaves; Patrick Wilson; Florian Krammer; Katherine Richards; Andrea J Sant
Journal:  NPJ Vaccines       Date:  2020-01-10       Impact factor: 7.344

Review 2.  CD4 T cells in protection from influenza virus: Viral antigen specificity and functional potential.

Authors:  Andrea J Sant; Anthony T DiPiazza; Jennifer L Nayak; Ajitanuj Rattan; Katherine A Richards
Journal:  Immunol Rev       Date:  2018-07       Impact factor: 12.988

3.  Discovery of novel cross-protective Rickettsia prowazekii T-cell antigens using a combined reverse vaccinology and in vivo screening approach.

Authors:  Erika Caro-Gomez; Michal Gazi; Yenny Goez; Gustavo Valbuena
Journal:  Vaccine       Date:  2014-07-07       Impact factor: 3.641

4.  Randomized peptide assemblies for enhancing immune responses to nanomaterials.

Authors:  Nicole L Votaw; Lauren Collier; Elizabeth J Curvino; Yaoying Wu; Chelsea N Fries; Madison T Ojeda; Joel H Collier
Journal:  Biomaterials       Date:  2021-04-15       Impact factor: 15.304

5.  Heterologous viral protein interactions within licensed seasonal influenza virus vaccines.

Authors:  Marina Koroleva; Frances Batarse; Savannah Moritzky; Carole Henry; Francisco Chaves; Patrick Wilson; Florian Krammer; Katherine Richards; Andrea J Sant
Journal:  NPJ Vaccines       Date:  2020-01-10       Impact factor: 7.344

Review 6.  The control of the specificity of CD4 T cell responses: thresholds, breakpoints, and ceilings.

Authors:  Andrea J Sant; Francisco A Chaves; Scott A Leddon; Jacqueline Tung
Journal:  Front Immunol       Date:  2013-10-23       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.